NBE-P2Alternative Names: New Biological Entity P2
Latest Information Update: 08 Oct 2008
At a glance
- Originator Direvo Biotech
- Class Peptide hydrolases
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 22 Jun 2005 This programme is still in active development - (BIO-2005)
- 22 Mar 2004 Early research in Inflammation in Germany (unspecified route)